XORTX Therapeutics Inc
$ 2.27
-6.97%
17 Apr - close price
- Market Cap 4,210,200 USD
- Current Price $ 2.27
- High / Low $ 2.45 / 2.21
- Stock P/E N/A
- Book Value 0.30
- EPS -2.80
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.47 %
- ROE -0.98 %
- 52 Week High 7.05
- 52 Week Low 1.73
About
XORTX Therapeutics Inc., a biopharmaceutical company, is dedicated to the development and commercialization of therapies to treat progressive kidney disease, hypertension, insulin resistance, and diabetic nephropathy. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$14.04
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-02 | 2025-11-13 | 2025-08-15 | 2025-05-14 | 2025-03-25 | 2024-11-12 | 2024-08-14 | 2024-05-15 | 2023-12-31 | 2023-11-14 | 2023-08-14 | 2023-05-15 |
| Reported EPS | -0.4507 | -0.1337 | -0.19 | 0.04 | -0.81 | -0.2022 | 0.0586 | 1.3504 | -0.636 | -0.67 | -0.8 | -0.11 |
| Estimated EPS | -1.58 | -0.316 | None | None | -0.41 | None | -0.923 | -0.2767 | -0.815 | -0.19 | -1.36 | -0.1456 |
| Surprise | 1.1293 | 0.1823 | 0 | 0 | -0.4 | 0 | 0.9816 | 1.6271 | 0.179 | -0.48 | 0.56 | 0.0356 |
| Surprise Percentage | 71.4747% | 57.6899% | None% | None% | -97.561% | None% | 106.3489% | 588.0376% | 21.9632% | -252.6316% | 41.1765% | 24.4505% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.08 | $0.07 | $0.08 | $0.08 | $0.08 | $0.07 | $0.07 | $0.07 | $0.05 | $0.05 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XRTX
2026-04-16 14:40:07
XORTX Therapeutics Inc. (NASDAQ: XRTX) has finalized the acquisition of Vectus Biosystems’ VB4-P5 kidney anti-fibrotic program for US$3.0 million, paid through a combination of common shares and pre-funded warrants. This deal adds a pre-Investigational New Drug (IND) small-molecule candidate aimed at kidney fibrosis, addressing a substantial unmet medical need in chronic kidney diseases. XORTX views this acquisition as a strategic expansion of its pipeline, potentially offering a new treatment to slow kidney disease progression and fibrosis.
2026-04-15 11:39:43
This article focuses on the long-term debt to total equity ratio of XORTX Therapeutics, Inc. (DUS:ANU). It appears to be a financial data page from TradingView, displaying key financial metrics for the company. The content primarily lists navigation and data source information rather than providing specific ratio values or analysis.
2026-04-14 18:09:07
This article briefly reports on the discontinued operations of XORTX Therapeutics, Inc. (DUS:ANU). It appears to be an automated notification or a placeholder as no further details are provided regarding the discontinuation. The content primarily consists of navigational elements and copyright information.
2026-04-14 11:39:43
XORTX Therapeutics Inc. has announced the closing of its acquisition of the Vectus kidney anti-fibrotic asset, including the novel chemical entity VB4-P5. This acquisition broadens XORTX's pipeline, targeting both rare and prevalent forms of kidney disease, an area with significant unmet medical need. The deal involves the issuance of common shares and pre-funded warrants, valued at an aggregate of US$3.0 million, aimed at developing therapies to slow kidney disease progression and accompanying fibrosis.
2026-04-13 20:39:10
XORTX (NASDAQ: XRTX) has finalized the acquisition of the VB4-P5 kidney anti-fibrotic asset from Vectus Biosystems for $3.0 million, paid in common shares and pre-funded warrants. This strategic move expands XORTX's pipeline into kidney anti-fibrotic therapeutics with a pre-IND stage novel chemical entity. The acquisition, which targets significant unmet needs in chronic and rare kidney diseases, was met with a positive market reaction, with XRTX stock gaining 5.88%.
2026-04-13 20:39:10
XORTX Therapeutics Inc. has completed the acquisition of the Vectus kidney anti-fibrotic asset, including the novel chemical entity VB4-P5, aimed at treating chronic kidney disease. This acquisition broadens XORTX's pipeline with a pre-IND stage program targeting both rare and prevalent kidney diseases with significant unmet medical need. The deal involved issuing 154,544 common shares and 692,150 pre-funded warrants to Vectus, totaling an acquisition price of US$3.0 million.
